Lonza Biologics Inc.

The oligonucleotide CDMO market is projected to grow from USD 2.51 billion in 2024 to USD 6.73 billion by 2029, with a CAGR of 21.8%. Key players include Thermo Fisher Scientific, Lonza, and Agilent Technologies. The market's expansion is driven by increasing demand for therapeutic, research, and diagnostic applications across pharma and biotech sectors.

The global biotechnology market, valued at USD 1,224.31 billion in 2022, is projected to reach USD 3,995.22 billion by 2032, growing at a 12.5% CAGR. It drives innovation in healthcare, agriculture, and environmental sustainability, with bio-pharmacy leading through precision medicine, biologics, and immuno-oncology. Despite regulatory and IP challenges, opportunities in personalized medicine and rare diseases are expanding. Key players include Novartis, Roche, and Biogen.

AI identified H3, a small molecule, reactivating p53-Y220C mutant, inhibiting tumor growth in mice. This highlights AI's potential in drug discovery for specific p53 mutations.

Panel discussions from 2024 highlight pharmaceutical trends, including mRNA advancements, CAR-T therapies, and the impact of political changes on healthcare. Key topics include measles outbreaks, FDA updates, Nobel Prize achievements, and investment in biotech. Discussions also cover drug pricing, vaccine access, and the effects of the Inflation Reduction Act.

FDA updates include recommendations for Advanced Manufacturing Technologies, IND approvals for IBI3009, and reopening comments on immunogenicity risk. Biologics R&D faces challenges and successes with bispecific antibodies. Bioprocessing advancements, microbial fermentation optimization, and real-world data trends impact pharmaceuticals. Hikma's liraglutide injection approved as first Victoza generic. WHO addresses COVID-19 vaccine updates. Roche introduces automated mass spectrometry.